SCHEDULE 13G/A: Biotechnology Value Fund Entities Disclose Significant Stake in GH Research PLC, Totaling 14.2% Ownership

Multiple entities associated with Biotechnology Value Fund, including Mark N. Lampert, have collectively reported beneficial ownership of 14.2% of GH Research PLC's ordinary shares as of March 31, 2025.

Summary

• Biotechnology Value Fund, L.P. (BVF) beneficially owns 4,599,019 shares, representing approximately 7.4% of GH Research PLC's outstanding shares.
• Biotechnology Value Fund II, L.P. (BVF2) beneficially owns 3,605,399 shares, representing approximately 5.8% of the outstanding shares.
• Biotechnology Value Trading Fund OS LP beneficially owns 619,881 shares, representing approximately 1.0% of the outstanding shares.
• BVF GP Holdings LLC (BVF GPH) is deemed to beneficially own 8,204,418 shares, or approximately 13.2% of the outstanding shares, through its control over BVF and BVF2.
• BVF Partners L.P., BVF Inc., and Mark N. Lampert are each deemed to beneficially own 8,827,712 shares, representing approximately 14.2% of the outstanding shares, through their shared voting and dispositive power over the holdings of BVF, BVF2, and Trading Fund OS.
• The percentages are based on 62,028,145 shares outstanding as of February 15, 2025, as disclosed in GH Research PLC's Form 20-F filed on February 27, 2025.
• This filing is an Amendment No. 2 to a Schedule 13G, indicating an update to previously reported ownership.

Sentiment

Score: 5

Explanation: The document is a factual disclosure of beneficial ownership, providing no inherent positive or negative sentiment regarding the issuer's performance or outlook. It is a neutral regulatory filing.

Future Outlook

NA

Industry Context

This filing indicates a significant passive investment by a specialized biotechnology fund in GH Research PLC, a company in the biotechnology sector. Such disclosures are common for institutional investors taking substantial, non-controlling stakes in public companies, often signaling confidence in the sector or specific company's long-term prospects.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional stake (14.2%) by a specialized biotechnology fund may be viewed positively by existing and potential shareholders, potentially signaling institutional confidence or interest in the company's value.

Key Dates

Keywords

GH Research PLC, Biotechnology Value Fund, BVF, Mark N. Lampert, SEC Filing, Schedule 13G, Beneficial Ownership, Institutional Investor, Equity Stake, Biotechnology, Pharmaceuticals